[go: up one dir, main page]

NO20092360L - Nye antiproliferasjonsantistoffer - Google Patents

Nye antiproliferasjonsantistoffer

Info

Publication number
NO20092360L
NO20092360L NO20092360A NO20092360A NO20092360L NO 20092360 L NO20092360 L NO 20092360L NO 20092360 A NO20092360 A NO 20092360A NO 20092360 A NO20092360 A NO 20092360A NO 20092360 L NO20092360 L NO 20092360L
Authority
NO
Norway
Prior art keywords
antibodies
novel
relates
present
antiproliferation antibodies
Prior art date
Application number
NO20092360A
Other languages
English (en)
Norwegian (no)
Inventor
Liliane Goetsch
Nathalie Corvaia
Jean-Francois Haeuw
Cedrik Bes
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of NO20092360L publication Critical patent/NO20092360L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
NO20092360A 2006-11-24 2009-06-19 Nye antiproliferasjonsantistoffer NO20092360L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0610329A FR2909092B1 (fr) 2006-11-24 2006-11-24 Nouveaux anticorps anti-proliferation
PCT/EP2007/062760 WO2008062063A1 (fr) 2006-11-24 2007-11-23 Nouveaux anticorps anti-prolifération

Publications (1)

Publication Number Publication Date
NO20092360L true NO20092360L (no) 2009-08-11

Family

ID=37903981

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092360A NO20092360L (no) 2006-11-24 2009-06-19 Nye antiproliferasjonsantistoffer

Country Status (27)

Country Link
US (2) US8071730B2 (fr)
EP (1) EP2074148A1 (fr)
JP (1) JP2010509931A (fr)
KR (1) KR20090088878A (fr)
CN (1) CN101535344B (fr)
AU (1) AU2007324509B2 (fr)
BR (1) BRPI0719323A2 (fr)
CA (1) CA2670039A1 (fr)
CL (1) CL2007003357A1 (fr)
CR (1) CR10788A (fr)
CU (1) CU23792A3 (fr)
EC (1) ECSP099341A (fr)
FR (1) FR2909092B1 (fr)
GE (1) GEP20125629B (fr)
GT (1) GT200900126A (fr)
IL (1) IL198744A0 (fr)
MA (1) MA30891B1 (fr)
MX (1) MX2009005293A (fr)
NI (1) NI200900079A (fr)
NO (1) NO20092360L (fr)
NZ (1) NZ576174A (fr)
RU (1) RU2451689C2 (fr)
SA (1) SA07280637B1 (fr)
TN (1) TN2009000194A1 (fr)
TW (1) TW200829602A (fr)
UA (1) UA99602C2 (fr)
WO (1) WO2008062063A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
WO2010002862A2 (fr) * 2008-07-01 2010-01-07 Aveo Pharmaceuticals, Inc. Protéines se liant au récepteur 3 du facteur de croissance des fibroblastes (fgfr3)
US8802827B2 (en) * 2009-10-30 2014-08-12 Merck Sharp & Dohme Corp. AX1 PCSK9 antagonists
AU2011320314B2 (en) * 2010-10-29 2015-08-06 Immunogen, Inc. Novel EGFR-binding molecules and immunoconjugates thereof
EP2455403A1 (fr) 2010-11-23 2012-05-23 Pierre Fabre Medicament Anticorps humanisés homogènes contre JAM-A qui inhibitent la prolifération
US20130287790A1 (en) * 2012-03-30 2013-10-31 The Board Of Trustees Of The Leland Standford Junior University Use of jam-a in diagnosing and treating leukemia
PL3489261T3 (pl) 2012-08-24 2021-08-16 The Regents Of The University Of California Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
KR20150097304A (ko) 2014-02-18 2015-08-26 삼성전자주식회사 항 EGFR DARPin을 포함하는 EGFR/HER2 이중 특이 항체
MX2018010445A (es) * 2016-03-01 2019-10-17 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Anticuerpos especificos del receptor de poliovirus humano (rvp).
CA3029003A1 (fr) 2016-06-27 2018-01-04 The Regents Of The University Of California Associations medicamenteuses pour le traitement du cancer
CA3032826A1 (fr) * 2016-08-03 2018-02-08 Nextcure, Inc. Compositions et procedes de modulation de la transduction du signal lair
CN109022366A (zh) * 2018-08-16 2018-12-18 江南大学 一株分泌抗左旋咪唑单克隆抗体的杂交瘤细胞株及其应用
CN114740108B (zh) * 2022-03-28 2023-07-14 天津键凯科技有限公司 一种聚合物修饰抗体类药物的修饰度的测定方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9604470D0 (sv) * 1996-12-04 1996-12-04 Tamas Bartfai Konsulting Ab Transmembrane component of tight junction
US6235883B1 (en) * 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US20030171568A1 (en) * 1998-09-16 2003-09-11 Avi Ashkenazi Use of A33 antigens and JAM-IT
JP3998419B2 (ja) * 1998-04-03 2007-10-24 中外製薬株式会社 ヒト組織因子（ｔｆ）に対するヒト型化抗体およびヒト型化抗体の作製方法
CN1637019A (zh) * 1999-03-11 2005-07-13 Rmf迪克塔吉恩有限公司 血管粘着分子及其功能的调节
WO2005060457A2 (fr) * 2003-12-04 2005-07-07 Pdl Biopharma, Inc. Traitement de maladies intestinales inflammatoires avec des anticorps anti-ip10
WO2006008076A2 (fr) * 2004-07-16 2006-01-26 Universita Degli Studi Di Milano Procedes et agents stimulant la reponse immunitaire
EP1888639A1 (fr) * 2005-05-12 2008-02-20 Oncotherapy Science, Inc. Procedes pour endommager des cellules en utilisant une fonction effectrice d un anticorps anti-dsc2
AU2007243196A1 (en) * 2006-04-28 2007-11-08 Oregon Health & Science University Monoclonal antibodies specific for pancreatic endocrine, exocrine or ductal cell

Also Published As

Publication number Publication date
HK1132752A1 (en) 2010-03-05
RU2009123409A (ru) 2010-12-27
GT200900126A (es) 2011-09-02
MX2009005293A (es) 2009-08-07
CA2670039A1 (fr) 2008-05-29
EP2074148A1 (fr) 2009-07-01
CN101535344B (zh) 2013-10-16
CR10788A (es) 2009-06-23
GEP20125629B (en) 2012-09-10
US8071730B2 (en) 2011-12-06
KR20090088878A (ko) 2009-08-20
TW200829602A (en) 2008-07-16
FR2909092B1 (fr) 2012-10-19
CL2007003357A1 (es) 2008-04-04
NI200900079A (es) 2010-11-10
UA99602C2 (ru) 2012-09-10
IL198744A0 (en) 2010-02-17
JP2010509931A (ja) 2010-04-02
BRPI0719323A2 (pt) 2014-02-04
CN101535344A (zh) 2009-09-16
SA07280637B1 (ar) 2012-04-11
NZ576174A (en) 2012-03-30
US20100092455A1 (en) 2010-04-15
FR2909092A1 (fr) 2008-05-30
WO2008062063A1 (fr) 2008-05-29
ECSP099341A (es) 2009-06-30
US20120156191A1 (en) 2012-06-21
AU2007324509A1 (en) 2008-05-29
AU2007324509B2 (en) 2013-01-17
RU2451689C2 (ru) 2012-05-27
TN2009000194A1 (en) 2010-10-18
MA30891B1 (fr) 2009-11-02
CU23792A3 (es) 2012-03-15

Similar Documents

Publication Publication Date Title
NO20092360L (no) Nye antiproliferasjonsantistoffer
UA102867C2 (uk) Антитіла до cxcr4 та їх застосування у лікуванні раку
NO20084396L (no) Kombinasjonsterapi
NO20082559L (no) Humane monoklonale antistoffer mot protein tyrosin kinase 7 (PTK7) og fremgangsmater for anvendelse av anti-PTK7 antistoffer
NO20081987L (no) Humane, monoklonale antistoffer mot CD70
BR112012025568A2 (pt) proteínas de ligação ao tnf-<244>.
NZ754051A (en) Novel antibodies and uses thereof
CY1119127T1 (el) Επιτοποι σκληροστινης
ATE449097T1 (de) Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer
UA97516C2 (ru) Полностью человеческое моноклональное антитело против vap-1
EA201170659A1 (ru) Антитела к рецептору ii tgf-вета
NO20083062L (no) Humane monoklonale antistoffer mot fukosyl-GM1 og fremgangsmater for anvendelse av anti-fukosyl-GM1
EA200801571A1 (ru) Композиции, содержащие молекулы ctl4-ig, и способы их получения
EA200971074A1 (ru) Антивирусные соединения
DE602005027258D1 (de) Humane monoklonale antikörper gegen hendra- und nipah-viren
NO20074446L (no) DR5-antistoffer og anvendelser derav
TW200740844A (en) Novel MAdCAM antibodies
MEP53308A (en) Novel peptides that bind to the erythropoietin receptor
NO20083053L (no) Humane monoklonale antistoffer mot O8E
EA200970477A1 (ru) Человеческие моноклональные антитела к btla и способы применения
EA200901138A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
NO20070487L (no) 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer.
NO20075849L (no) Fremgangsmater og preparater til behandling eller forebygging av kreft
EA201170590A1 (ru) Ингибиторы рецептора фактора роста фибробластов-3 (fgfr-3) и способы лечения
WO2008027739A3 (fr) Anticorps vis-à-vis de ntb-a

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application